Imtherapeutics
1 known investors
Imtherapeutics develops oral therapies for Type 1 diabetes patients with specific genetic markers. The company's AMT-002 candidate is designed to selectively block autoantigens that trigger autoimmunity in patients with the HLA-DQ8 genetic allele.
Investors · 1
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $225K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Imtherapeutics do?
- Imtherapeutics develops oral therapies for Type 1 diabetes patients with specific genetic markers. The company's AMT-002 candidate is designed to selectively block autoantigens that trigger autoimmunity in patients with the HLA-DQ8 genetic allele.
- Who are Imtherapeutics's investors?
- Imtherapeutics's investors include JDRF T1D Fund.